Free Trial

CONSUMER CYCLICALS: Remy Cointreau reports rough results

CONSUMER CYCLICALS

The Cognac name has cut FY (to April 2025) guidance from a "gradual recovery over the course of the year" to a double digit sales decline. 1H sales were -18% in Cognac and -12% in other spirits, led by US (-23%) and EMEA (-19%). APAC/China holding better (-8%) for now. It sees recovery only early next year in US, none in EMEA and for APAC to deteriorate. Margin guidance has gone from stable to deterioration.

Credit issuer comps (Campari, Diageo & Pernod) equities are holding flat this morning. We hope above gives some context on why we still see Campari as relative outperformer - even after rough Q3 results (some of it one one-offs) it has outperformed peers YTD. Guidance from it is LSD organic growth and EBIT margin contraction of ~less than 200bps this year. Unrated 27s trade at B+165/Z+139/3.5%.

140 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.

The Cognac name has cut FY (to April 2025) guidance from a "gradual recovery over the course of the year" to a double digit sales decline. 1H sales were -18% in Cognac and -12% in other spirits, led by US (-23%) and EMEA (-19%). APAC/China holding better (-8%) for now. It sees recovery only early next year in US, none in EMEA and for APAC to deteriorate. Margin guidance has gone from stable to deterioration.

Credit issuer comps (Campari, Diageo & Pernod) equities are holding flat this morning. We hope above gives some context on why we still see Campari as relative outperformer - even after rough Q3 results (some of it one one-offs) it has outperformed peers YTD. Guidance from it is LSD organic growth and EBIT margin contraction of ~less than 200bps this year. Unrated 27s trade at B+165/Z+139/3.5%.